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In the EU, development of new medicines for children should follow a
prospectively agreed paediatric investigation plan (PIP). Finding the right
dose for children is crucial but challenging due to the variability of
pharmacokinetics across age groups and the limited sample sizes available.
We examined strategies adopted in PIPs to support paediatric dosing
recommendations to identify common assumptions underlying dose
investigations and the attempts planned to verify them in children.
METHODS
We extracted data from 73 PIP opinions recently adopted by the Paediatric
Committee of the European Medicines Agency. These opinions represented
79 medicinal development programmes and comprised a total of 97 dose
investigation studies. We identified the design of these dose investigation
studies, recorded the analyses planned and determined the criteria used to
define target doses.
RESULTS
Most dose investigation studies are clinical trials (83 of 97) that evaluate a
single dosing rule. Sample sizes used to investigate dose are highly variable
across programmes, with smaller numbers used in younger children (< 2
years). Many studies (40 of 97) do not pre-specify a target dose criterion. Of
those that do, most (33 of 57 studies) guide decisions using
pharmacokinetic data alone.
CONCLUSIONS
Common assumptions underlying dose investigation strategies include
dose proportionality and similar exposure−response relationships in adults
and children. Few development programmes pre-specify steps to verify
assumptions in children. There is scope for the use of Bayesian methods as
a framework for synthesizing existing information to quantify prior
uncertainty about assumptions. This process can inform the design of
optimal drug development strategies.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Paediatric dose investigations pose
methodological and ethical challenges.
• Where appropriate, paediatric dosing
recommendations should be informed by
existing data.
WHAT THIS STUDY ADDS
• A variety of strategies are used to support
paediatric dosing recommendations
reflecting differing amounts of caution
about dose.
• Pre-specified strategies for verifying
extrapolation assumptions in children are
often undefined.
• There is scope for using Bayesian methods
to quantify prior knowledge when there is
uncertainty about extrapolation
assumptions.
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Introduction
Recent regulatory changes place greater emphasis on
ensuring that new medicines are appropriately licensed
for use in children. The EU Paediatric Regulation (EC 1901/
2006) mandates the development of new medicinal prod-
ucts in children from birth to 18 years where there is a
therapeutic need. Development should follow a prospec-
tively agreed paediatric investigation plan (PIP). This plan
must be submitted by an ‘applicant’ for the consideration
of the Paediatric Committee (PDCO) of the EuropeanMedi-
cines Agency (EMA) no later than completion of the adult
pharmacokinetic (PK) studies; requests for a waiver of
development must be justified. Most applicants are phar-
maceutical companies.
Finding an appropriate dosing rule for a new medicine
is crucial if its benefits are to be properly evaluated. Not-
withstanding the ethical challenges, there are several
methodological challenges peculiar to dose finding in chil-
dren. Differences in the pharmacokinetics and pharmaco-
dynamics of a drug across age groups, reflecting changes
in developmental growth andmaturation [1, 2], may result
in differences in possible clinical benefit. Relationships
between bodyweight and pharmacokineticsmay also vary
with age [3]. Information on drug pharmacokinetics and
pharmacodynamics, therefore, is usually needed across all
ages concerned by development to identify subgroups for
which different optimal dosing rules apply. The ICH E11
guideline [4] proposes one possible age grouping, classify-
ing children as neonates (0–27 days); infants (1–23
months); children (2–11 years) or adolescents (12–17
years), but cautions that unnecessary age subdivisionsmay
unnecessarily increase the number of patients required.
The experimental effort needed to support dosing rec-
ommendations in children should be relative to the uncer-
tainty that exists about likely drug effects in this
population at the time a PIP is designed. If a medicine is
first in class, that is, has a novel mechanism of action, or is
intended to treat an exclusively paediatric condition,
investigators may have little to guide them about the
likely form of the dose−response or pharmacokinetic-
pharmacodynamic (PK-PD) relationship. In such cases,
dose finding trials in children should be designed account-
ing for this uncertainty, perhaps evaluating multiple
dosing rules chosen to enable accurate model fitting and
estimation under a variety of plausible models [5]. In the
case of dose escalation studies, escalation over a dosing-
set that is usually limited in children compared with adults
may be guided by accumulating PK or PD data to increase
efficiency and safety [6]. Acceptable designs for dose
finding trials in children may be shaped by ethical consid-
erations or constraints on feasible sample sizes, where the
latter may apply when diseases are rare.
Fewer doses may be sufficient to establish the
dose−efficacy relationship in children if one can extrapo-
late from data in a related population. In addition, PD or PK
endpoints may be used as surrogates for efficacy. To illus-
trate this, suppose one can assume exposure−response
(E−R) relationships are similar in adults and children. Then
anoptimal dosing strategy in children is foundby targeting
in every age group levels of exposure thought to be effica-
cious and safe in adults. This approach has been termed
‘complete extrapolation’ of efficacy data [7] and has been
used successfully to support paediatric approval of the
anti-epileptic drug oxcarbazepine [8]. If relevant data are
numerous, the need for a clinical trial in children may be
obviated entirely, with dosing rules supported by model-
ling and simulation (M&S) alone. The value of M&S for
optimizing paediatric drug development is recognized
[9, 10].
When data are extrapolated from a related population
(referred to as the source population) to children (referred
to as the target population), the quality of inferences about
children depends both on the accuracy of the assumptions
underpinning the extrapolation and the quality of the
extrapolated data. Complete extrapolation of efficacy from
adults to children is not possible if the adult E−R relation-
ship is poorly characterized [11]. An EMA concept paper
[12] proposes using emergingdata to corroborate assump-
tions as part of an overarching framework for extrapola-
tion. We distinguish between verifying and validating
assumptions, where the former implies generating sup-
portive evidence and the latter definitive evidence.
We have undertaken a review to explore current strat-
egies adopted in PIPs to support paediatric dose recom-
mendations. Our aim was to record common assumptions
underlying dose investigation strategies and the steps
planned to verify them in the paediatric population. When
study results have been reported, we can then evaluate
the usefulness of various strategies for dose selection.
Methods
A PIP application must detail the condition, indication(s)
and age group concerned by development and outline all
of the studies intended to support this. If an application
proposes that themedicine treatmore than one condition,
a PIP must be specified for each condition targeted. If the
PDCO judges a PIP to be acceptable, or can agree upon
suitable modifications with the applicant, it adopts a
positive PIP opinion. An opinion is a formal document
summarizing the binding elements of the agreed develop-
ment plan.
Information for this review was extracted from opin-
ions and, where necessary, PIP applications and applicant
responses to PDCO comments. Opinions are publicly
available at http://www.ema.europa.eu/ema/index.jsp
?curl=pages/medicines/landing/pip_search.jsp&mid=WC
0b01ac058001d129. One author (LH) extracted the data
seeking advice from others (RH, JS) on an ad-hoc basis.
The protocol, data extraction form and pre-specified
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analysis plan for the review can be found in the supple-
mentary material accompanying this manuscript. All sta-
tistical analyses were performed in R [13].
This review focused on clinical ‘dose investigation’
studies stipulated by PIP opinions. We adopted a broad
definition of dose investigation study to include clinical
trials that a) state a dose finding objective in the opinion or
are cited as informing dose choices for subsequent trials or
b) compare two or more dosing rules or c) measure PK end
points. We included stand alone trials and portions of
multistage trials. Furthermore, we regarded the following
extrapolation approaches as dose investigating: a) PK,
PK−PD or dose-PD M&S studies, b) prospective literature
reviews gathering information on effective medicine use
in children and c) use of completed paediatric dose inves-
tigation trials when listed in the opinion. Table 1 lists the
terminology used in this paper.
We excluded from our definition of dose investigation
study a) pre-clinical studies (including ex vivo studies), b)




Dose evaluation study Evaluates single dosing rule with the objective of verifying its pharmacological properties
Example: See example A of the fixed dose strategy trial
Dose finding study Evaluates multiple dosing rules to establish the dose-response relationship
Example: See example B of the fixed dose strategy trial
Dose investigation study General term encompassing dose evaluating and dose finding studies
Dosing rule A rule specifying the amount of medicine to be given (and the administration schedule) in all age groups concerned by medicinal
development. For example, if the dosing rule is x1 mg kg−1, different rules are defined by varying x1.
Fixed dose strategy trial Trial evaluating a number of pre-specified dosing rules of a novel medicine. Trial may incorporate a control arm. Intra-individual
dose adaptation permitted at a limited number of time points, with adjustments guided by PK/PD/efficacy responses
Example A: Participants aged 1 month to less than 18 years receive novel drug according to the same regimen for 14 days. PK
samples collected across day 14; safety and tolerability measured throughout.
Example B: Double-blind, randomized, multicentre trial to compare the efficacy of two dose levels of a novel treatment with
placebo and (one dose level of) active control.
Example C: Initial doses for participants aged from 2 to less than 18 years set by weight categories. Treatment maintained for 2
years but PK measured within first 14 days of treatment. In-stream adjustment of individuals’ doses permitted if individual PK
parameters deviate from predicted values based on adult PK data.
Maximum tolerated dose (MTD) The highest dose associated with an acceptable risk of toxicity. The 3+3 dose escalation procedure [19], which treats patients in
cohorts of three, finds the MTD as follows. Suppose doses {d1, d2, . . ., dK} are available for consideration. If two or more of the
first three patients treated at a dose level di experience a dose limiting toxicity (DLT), the procedure stops declaring di-1 as the
MTD. Otherwise, if one of the three patients treated with di experiences a DLT, a further three patients are treated at this dose
level. Then, if two or more of the six patients treated at dose level di experience a DLT, the procedure stops declaring dose di-1 as
the MTD. If continuation of the trial is permitted, the procedure escalates to treat the next cohort at dose di+1.
Non-randomized crossover trial Each patient is treated according to two different dosing rules which are administered in the same sequence to all patients. Total
dose received need not escalate between successive dosing periods
Example: All participants from birth to less than 18 years of age receive study medication twice daily for 4 weeks, followed by a 4
week treatment period of once daily dosing. In each treatment period, patients receive up to 2 mg kg−1 day−1 of study medication
(so the dosing schedule varies over periods but total amount of drug received per day is held constant). Trial objective is to
compare the pharmacokinetics of once daily dosing vs. twice daily dosing.
Sequential cohort dose
escalation trial
Patients are treated in cohorts. Successive cohorts either escalate through a set of dosing rules (forced dose titration) or escalation
decisions are determined by trial data
Example A: Five cohorts of eight adolescents enrolled sequentially. Patients in a cohort receive the same dose. Doses received by
cohorts 1 to 5 escalate from 0.5 mg to 5 mg, respectively. Patients treated for 14 days. (Fixed dose phase may be preceded by
dose titration phase depending on maximum dose for the cohort.)
Example B: Patients aged from 1 to less than 18 years enrolled in cohorts of three. Dose escalation proceeds on the basis of a 3 +
3 design [19], with dose recommendations for the next cohort determined by accumulated trial data, specifically dose limiting
toxicities experienced by patients in their first cycle of therapy. Starting dose is 80% of adult MTD, with scaling based on body
surface area.
Target dose criterion Criterion defining dosing rule sought by the dose investigation study or the dosing rule that will be taken forward for use in
subsequent trials (or to inform labelling).
Therapeutic dose monitoring
(TDM) trial
Trial stipulating a flexible dosing strategy adapting to patients’ efficacy/PD/PK response, with no fixed dosing rule envisaged
Example: In children aged 2 to less than 18 years, starting daily doses will be body surface area equivalent of 6g day−1 in adults.
Thereafter, study medication is to be titrated up and down as needed following a developed scheme to maintain age appropriate
levels of an efficacy endpoint. Trial objective is to determine the initial starting doses of study medicine for children.
Within-subject dose escalation
trial
Each patient is treated according to multiple dosing rules. Successive doses either escalate through a pre-specified set (forced dose
titration) or escalation decisions are determined by trial data.
Example: Patients aged 8 to less than 18 years initiated on 2.5 mg of study medication. Dosing then doubled at 4 weekly intervals,
with escalation decisions determined by accumulating safety and tolerability data. PK assessments made throughout period of
dose escalation. Treatment at an individual’s MTD is maintained until week 24.
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(TDM) trials without a stated dose finding objective and d)
efficacy bridging studies not making explicit mention of
pharmacological modelling.
From each PIP, information was extracted about all
studies classified as dose investigating according to our
stated criteria. If a PIP stipulated two dose investigation
studies to determine dosing rules for the medicine when
administered as monotherapy and adjunctive therapy, we
extracted information for both.
If an opinion covered more than one condition, we
extracted information for each unique PIP specified. If
there was some overlap between the clinical studies com-
prising PIPs for different conditions, we recorded for each
PIP only the most relevant dose investigation study(s),
where ‘most relevant’ meant that studies conducted in a
much broader population were not counted. For example,
suppose a PIP application targeted two conditions: solid
tumours excluding melanoma and melanoma. If a dose
escalation study was planned in patients with all types of
solid tumour, along with a M&S study to establish dose in
melanoma patients, we would record the first study as
dose investigating for solid tumours excluding melanoma
but only the second study as dose investigating for mela-
noma. This type of scenario concerned three PIP applica-
tions. Henceforth, we will refer to PIPs as ‘development
programmes’.
We hypothesized that rare diseases are a trigger for
extrapolation as applicants seek to augment small sample
sizes. For a medicine to be recommended for an orphan
designation by the EMA Committee for Orphan Medicinal
Products, amongst other criteria the treated condition
must not affect more than 5 in 10 000 people in the EU
[14]. We used amedicine’s orphan status as a surrogate for
the prevalence of the condition to be treated. However, an
applicant is at liberty to seek an orphan designation for its
product at any point during development before market-
ing authorization.We accorded amedicine orphan status if
designations had previously been recommended for other
medicines treating at least one of the conditions or indica-
tions targeted by the PIP. This information was extracted
from the EMA online database of orphan recommenda-
tions [15] on 27 February 2013.
Results
We extracted information from the last 74 opinions agree-
ing a PIP that had been adopted by the PDCO as of 20 July
2012, spanning a period of about 14 months, excluding
opinions granting a full development waiver. Of the opin-
ions reviewed, one was excluded because dose investiga-
tions were judged unnecessary by the authors of this
manuscript. The review focused on the remaining 73 opin-
ions, representing 79 ‘development programmes’ span-
ning 17 therapeutic areas (TAs; see Table 2). Of these, 29
programmes concerned orphan medicines and 14 con-
cerned medicines already holding a marketing authoriza-
tion in the EU. Sixty-eight (of 79) programmes planned at
least one dose investigation study and 59 (of 79) planned
dose investigations in every age group for whom use of
the medicine was considered relevant by the PDCO. Sixty-
eight programmes investigating dose planned a total of 97
dose investigation studies.
Design of dose investigation studies
Table 3 classifies dose investigation studies according to
their design. Supplementary Tables 1 and 2 summarize
the 83 dose investigation studies that were clinical
trials according to the data sources used to determine
starting doses and measured end points. One type of
dose investigation study is an extrapolation exercise (as
defined in the Methods section above). Programmes
using extrapolation to investigate dose covered the




Many dose investigation studies (40/97) were dose
evaluating in nature rather than dose finding. For this
Table 2




Pneumology-allergology/infectious diseases 11 (13.9%)
Immunology-rheumatology-transplantation 10 (12.7%)
Psychiatry/neurology 9 (11.4%)




Regulatory status of the medicine
Medicines that are not yet authorized in the EU‡ 65 (82.3%)








†Percentages sum to > 100% as the condition targeted by a PIP may cover
more than one therapeutic area. *The category ‘Other’ covers the following
therapeutic areas: gastroenterology-hepatology, diagnostic, dermatology, ophthal-
mology, neonatology-paediatric intensive care, uro-nephrology and ‘other’.
‡Including medicines where the patent has expired and the development of the
product in children is voluntary.
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approach to be pertinent there should be a high degree
of confidence in the proposed dosing rule. Otherwise,
if it is found to be inadequate, the findings of a single
arm PK study can be extrapolated to inform selection of
an alternative dosing rule only under strong assumptions,
i.e. assumptions that have far reaching clinical conse-
quences yet are supported by limited evidence, in this
case dose proportionality. Under this assumption expo-
sure, i.e. area under the curve (AUC), is a constant multi-
ple of dose; see Section 7.3 of [16]. However, this cannot
be verified using data from a single arm study. Twelve (of
40) of the fixed dose evaluating trials planned an interim
analysis for dose confirmation, reflecting a degree of
caution about dose. In Table 3, these 12 trials are classi-
fied according to the minimum number of dosing-rules
evaluated.
Of the 18 fixed dose strategy trials evaluating two or
more dosing rules, 14 and four trials planned to compare
two and three rules, respectively. Comparing few dosing
rules limits the complexity of any dose−response model
that can be fitted: if two rules are compared, a linear
model is the most complex description of the data
possible.
Adaptive designs provide investigators with the flex-
ibility to respond to emerging trial data and M&S is a
useful tool to guide adaptations. Of the 23 fixed dose
strategy trials that planned to stagger recruitment into
vulnerable subgroups, 13 will use accumulating data to
modify starting doses for later groups. Of these 13 trials,
nine will use M&S to guide dose changes. However, few
dose escalation trials planned to incorporate M&S into
decision making. Instead almost all (21/22) will use algo-
rithmic rules, unspecified safety analyses or unspecified
PK analyses to guide escalation decisions.
Efficacy trials give an opportunity for proposed dosing
rules to be assessed against clinical outcomes. A high
proportion of dose investigating programmes (50/68)
included trials labelled (in the opinion) as investigating
efficacy, activity or immunogenicity in every age group
concerned by development. This proportion drops in pro-
grammes using extrapolation (5/14).
Sample sizes supporting dose
recommendations
Opinions stipulate total trial sample sizes, often stratified
by age cohort to ensure there is a good reflection of the
target population in the trial. We extracted this informa-
tion to investigate whether the experimental effort used
to support dose recommendations varies with age. We
excluded from our analysis 19 (of 68) programmes that
included one or more dose investigation clinical trial not
providing information on the distribution of patients
across age groups. Figure 1 plots kernel density estimates
for cumulative sample sizes planned across dose investi-
gation studies included in the remaining 49 (of 68) pro-
grammes. For this analysis, extrapolation exercises were
recorded as recruiting 0 patients in every age group con-
cerned by the exercise. For all other studies, sample sizes
were broken down according to the ICH E11 age classifi-
cation. If age cohorts stipulated by opinions did not coin-
cide with the ICH E11 groupings, sample sizes for these
groups were calculated assuming that within each cohort
that was stipulated, recruitment would be evenly spread
across the age range. Only programmes developing a
medicine for use in the stated ICH E11 age group (as
stipulated by the PIP opinion) were included in this
sample size analysis.
For 11 trials within the 49 programmes, opinions stipu-
lated minimum sample sizes per age cohort (summing to
less than the required total sample size). In these cases we
assumed that the sample size at the applicant’s discretion
would be recruited from the oldest age group under
Table 3
Designs of 97 dose investigation studies planned by 79 paediatric development programmes. Listed are the median and interquartile range (IQR) of the
median ages to be recruited in the different studies (or the median ages study conclusions apply to in the case of extrapolation exercises)
Dose investigation study design
Number of studies (by




per study (IQR)Orphan Non-orphan
Sequential cohort dose escalation trial (with intra-subject escalation) 2 (5.0%) 1 (1.8%) 15 (2.8) 30 (18)
Sequential cohort dose escalation trial (without intra-subject escalation) 6 (15.0%) 5 (8.8%) 9.3 (0.5) 40 (24.5)
Within subject dose escalation trial 4 (10.0%) 4 (7.0%) 11 (2.9) 22 (15)
Non-randomized cross-over trial 1 (2.5%) 0 9 (0) 15 (0)
Fixed dose strategy trial (> 1 dosing rule of novel medicine) 5 (12.5%) 13 (22.8%) 11.3 (5.1) 61.5 (93)
Fixed dose strategy trial (1 dosing rule of novel medicine) 15 (37.5%) 25 (43.9%) 9.6 (2.6) 30 (18.5)
TDM trial 1 (2.5%) 1 (1.8%) 8 (2) 47.5 (2.5)
Extrapolation exercise: 6 (15.0%) 8 (14.0%) 9.3 (4.6) 0
• M&S study 2 5
• Prospective literature review 2 1
• Citation in PIP of completed paediatric dose investigation trial in current medicine 2 1
• Citation in PIP of completed paediatric dose investigation trial in related medicine 0 1
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development. This tacitly assumes that older children are
more readily recruited. The results of Figure 1, therefore,
represent a worst case analysis.
There is a clear discrepancy between the sample sizes
used to investigate dose in younger (<2 years) and older
(>2 years) children. We infer that it is common to extrapo-
late evidence across age groups to support dose recom-
mendations in the youngest children. Sample size
distributions in older children are multimodal because a
number of programmes planned large dose-ranging trials
in these groups. These programmes covered the TAs
pneumology-allergology, psychiatry, neurology and
uro-nephrology.
When PK parameters are measured, the precision of
the parameter estimates will depend on sample size and
sampling intensity, where the latter may also vary with
age. We defined a PK study as a trial declaring PK as either
a primary or secondary end point. Figure 2A displays the
cumulative numbers of patients participating in PK studies
for the 25 (of 68) programmes that included PK studies
stratifying recruitment by age and stipulating a sampling














































Densities of cumulative sample sizes accrued across dose investigation studies planned by programmes developing in an age group and stratifying
recruitment. Listed are numbers of programmes developing in each age group. The sample size range is [0−40] in the top panel and [0−150] in the bottom.
Overall median samples per age group are: 0.1 aged 0–27 days; 2.9 aged 1–23months; 10.0 aged 2–11 years; 9.0 aged 12–17 years. , overall; , orphan;
, non-orphan
(A) 0–27 days; 15 programmes. (B) 1–23 months; 23 programmes, (C) 2–11 years; 41 programmes and (D) 12–17 years; 47 programmes
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numbers of the youngest and oldest children participating
in PK studies. Figure 2B shows that there is a strong posi-
tive association between age and the median number of
PK samples per patient.
Analysis of dose investigation studies
Modelling provides a more informative summary of the
data from a dose investigation trial than descriptive statis-
tics alone could give [17]. Table 4 summarizes themethods
of analysis cited by 81 dose investigation trials measuring
at least one efficacy, PD or PK end point. PK modelling is
widely applied, although complex physiologically based
models are seldom fitted. For 23 trials, paediatric data will
be pooled with adult data or observations from other pae-
diatric trials to obtain greater precision for model param-
eter estimates.
Target dose criterion
Table 5 lists the target dose criterion stated for 97 dose
investigation studies. PK data alone will be used in 33
studies to guide dose selection with most (25/33) deter-
mining dosing rules by targeting levels of exposure seen in
older subjects. Few of the 33 studies that were clinical trials
pre-specified steps for verifying an assumption of similar
E-R relationships in a source population and children: 20
(of 29) trials will measure an efficacy or PD endpoint and
six of these will model the E−R relationship.
Other stated target dose criteria were vague. The
maximum tolerated dose (MTD) [18], as determined by
algorithmic dose escalation procedures such as the 3 + 3
design [19], is not well defined in the sense that it does not
correspond to a fixed probability of a dose limiting toxicity
(DLT). Indeed, the 3 + 3 design and close variations on it
may terminate with an MTD associated with a DLT risk of
10–29% [20]. A target dose criterion could not be deter-
mined for a high proportion of studies, particularly for
those studies developing orphan medicines. By not pre-
specifying a target criterion, applicants are flexible to

















































(A) Cumulative numbers of patients contributing PK information and (B) median numbers of PK samples per patient in 25 programmes conducting at least
one PK trial, stratifying randomization into PK studies by age and stipulating intended sampling schedules. Numbers in each age group are based on
programmes developing in that age group. Three (of 25) programmes obtain (some) PK samples from urine or saliva.
(A) Cumulative PK patient numbers. , total; , 0–27 days; , 1–23months; , 2–11 years; , 12–17 years and (B)median numbers of PK samples per patient.
, non-orphan; , orphan
Table 4
Techniques to be used to analyze 81 dose investigation studies that were
clinical trials measuring at least one efficacy, PD or PK end point
Analysis technique
Descriptive analyses
summary statistics including confidence intervals;
graphics; summaries of PK or PD parameters
73 (90.1%)
PK modelling
fixed effect or population PK models
41 (50.6%)
PK–PD modelling
including exposure–response, PK–response models
17 (21.0%)
Dose–response modelling
including dose-PD (e.g. ANCOVA model),
dose–toxicity, dose–PK–PD models
10 (12.3%)
Physiologically-based PK modelling 3 (3.7%)
Dose–exposure modelling 3 (3.7%)
Other
Formal hypothesis testing on efficacy or PD end
points; non-parametric time-to-event analyses;
other types of models not captured above
22 (27.2%)
L. V. Hampson et al.
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particular study design will be adequate to address the
ultimate dose finding objective.
Discussion
Few children less than 2 years of age contribute to dose
investigations, suggesting that this age group is currently
under researched. This is in conflict with recent FDA guid-
ance that paediatric PK studies should have adequate
precision for estimating relevant parameters in every age
group under consideration [21]. Figure 1 provides evi-
dence to support our initial hypothesis that sample sizes
are related to the prevalence of the condition treated and
anticipated recruitment difficulties. However, extrapolat-
ing to children with rare diseases can be challenging due
to the limited amount of adult data available. Alterna-
tively, rare disease trials in children may recruit across
similar conditions to increase the sample numbers
available, an accepted practice in early phase oncology
trials.
Bayesian methods [22] were rarely cited to support
development programmes included in this review. Of the
dose investigation studies included, one cited Bayesian
methods for study analysis and one to guide mid-trial
dosing adaptations. In the Bayesian paradigm, before a
trial is conducted prior probability distributions for
unknown parameters are determined from expert opinion
or historical data. Once new data become available, priors
are updated to form posterior distributions. The advan-
tage of using Bayesian designs for paediatric trials is that
they provide a framework through which prior knowledge
can be quantified and uncertainty, for example, about the
size of differences between the source and target popula-
tions of an extrapolation, can be communicated. This
‘extrapolation concept’, adopting the terminology of the
EMA concept paper on extrapolation [12], may be used to
inform selection of an appropriate extrapolation strategy,
although selection will also be informed by the feasibility
and ethics of generating additional data in the target
population. The EMA concept paper on extrapolation [12]
proposes that ‘studies should focus on those complemen-
tary areas, e.g. age subsets, where the largest differences
to the source population are expected’. We refer to this as
‘stochastic extrapolation’.
Numerous Bayesian approaches have been proposed
in the statistical literature for the design of paediatric [23,
24] and rare disease trials [25–27]. With the Bayesian
approach there is a trade-off between the gain in precision
of estimates and the dependence of posterior inferences
on the prior distribution. There is caution amongst statis-
ticians and regulators about the use of informative priors
to interpret the results of clinical trials [17], although we
contend that the influence of an informative prior should
not be a concern if the prior is well-founded. For this to be
true, prior distributions for parameters in children should
be determined by a rigorous assessment of what is already
known, including pre-clinical data and knowledge of class
effects when determinants of the pharmacokinetics and
pharmacodynamics of a class of drugs, and the effect of
age, are well understood. In the UK public health sector,
funding applications for clinical trials must be supported
by a systematic review of existing literature [28]. A similar
guideline could be stipulated for PIP applications to
ensure that there is an objective framework within which
existing sources of related data can be identified and their
relevance assessed. Quantifying the current state of
knowledge will help to inform dose selection decisions
when evidence generation in the target population is
deemed unethical or definitive sample sizes are not feasi-
ble, as may be the case, for example, when diseases
are rare.
The paediatric decision tree (see Section 2.4 of [4]) does
not accommodate uncertainty about extrapolation
assumptions. If an assumption is deemed reasonable,
applicants proceed by treating it as fact. We refer to this as
‘deterministic extrapolation’. In this framework, strong
assumptions remain unverified because they preclude
from being collected those data that could reveal incon-
sistencies between the assumptions and the true state of
nature. A stochastic approach to verifying assumptions
allows updating of the measures of uncertainty about
dose−response.
One limitation of this review is that data were extracted
by a single author, although this was not a major concern
because opinions are highly structured. The review also
concerns a small subset of the more than 600 PIP opinions
to have been adopted by the PDCO since 2007. A compre-
hensive review of all PIPs was deemed infeasible. There-
fore we chose to restrict attention to a contemporary
subset. However, further research could examine changes
in dose investigating strategies since 2007. While beyond
the scope of the current paper, it would also be of interest
to follow up those PIPs which were surveyed to determine
which data were ultimately most informative for devising
an appropriate dosing regimen.
Table 5
Target criteria to be used by dose investigation studies conducted by 79
paediatric development programmes. Data from a total of 97 studies
were extracted
Dose criteria
Number of studies (by rarity of disease)
Overall Orphan Non-orphan
PK guided 33 (34.0%) 9 (22.5%) 24 (42.1%)
PK and PD/efficacy guided 10 (10.3%) 3 (7.5%) 7 (12.3%)
Maximum tolerated dose 7 (7.2%) 6 (15.0%) 1 (1.8%)
Optimum biologic dose† 4 (4.1%) 1 (2.5%) 3 (5.3%)
Other 3 (3.1%) 1 (2.5%) 2 (3.5%)
Not known 40 (41.2%) 20 (50.0%) 20 (35.1%)
†Optimum biologic dose is one defined on the basis of PD or efficacy end points.
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The 79 development programmes included should not
be interpreted as independent research plans. There will
be orthodoxies for investigating dose in certain diseases
that all PIPs will follow, driven by regulatory guidelines and
precedents established by the PDCO. Adopted dose inves-
tigation strategies may reflect a compromise between the
strategies of the applicant and those of the PDCO. This
review excluded pre-clinical studies, which in relevant
model systems may contribute towards an understanding
of the possible differences between adults and children.
However, they may be more relevant for safety questions.
This review has noted only what steps are pre-specified for
verifying assumptions directly in the paediatric popula-
tion. The data collected by this review do not allow us to
comment onwhether additional studies should have been
specified for verification of assumptions.
The conclusions of this review presume that the infor-
mation provided in PIP applications and opinions gives an
accurate picture of how studies were designed and will
proceed. If relevant information was omitted from appli-
cations this could bias our results. Specifically, applicants
may eventually take steps to verify extrapolation assump-
tions in children, such as PK−PDmodelling, whichwere not
pre-specified in the PIP.
Conclusion
A variety of strategies are used to investigate dose in chil-
dren, with small sample sizes used in children less than 2
years old. Common assumptions underlying dose investi-
gation strategies include dose proportionality and similar
E−R relationships in children and a source population.
There is scope for the increased use of pharmacological
modelling as a tool for verifying extrapolation assump-
tions. Future research would develop a framework for
prospectively determining what studies are needed in
children given existing data in adults and other
populations.
Competing Interests
All authors have completed the Unified Competing Inter-
est form at http://www.icmje.org/coi_disclosure.pdf (avail-
able on request from the corresponding author) and
declare LVH reports grants from the UK Medical Research
Council (grant MR/J014079/1) during the conduct of the
study, grants and other from the Pharmaceutical Industry
outside the submitted work. AW reports grants from the
UK Medical Research Council (strategic grant G0800792/
87129) during conduct of the study, grants and other from
the Pharmaceutical Industry outside the submitted work.
MP reports grants and personal fees from Novartis Pharma
AG, personal fees from Finox AG, Burgdorf, Switzerland/
Polymun Scientific Immunobiologische Forschung GMBH,
Wien, Austria, and from Intercall AG, outside the submitted
work. RH and JS have nothing to disclose. This work is





The views expressed in this article are the personal views
of the author(s) and may not be understood or quoted as
being made on behalf of or reflecting the position of the
EMA or one of its committees or working parties.
The authors wish to thank the EMA Paediatric Commit-
tee for helpful discussions and Dr Thomas Jaki for com-
ments on an earlier draft of the manuscript. The authors
also thank two anonymous referees and the Executive
Editor for comments which improved the clarity of the
manuscript.
REFERENCES
1 Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the
right dose for children? Br J Clin Pharmacol 2010; 70:
597–603.
2 De Cock RFW, Piana C, Krekels EHJ, Danhof M, Allegaert K,
Knibbe CAJ. The role of population PK-PD modelling in
paediatric clinical research. Eur J Clin Pharmacol 2011; 67
(Suppl. 1): S5–16.
3 Cella M, Zhao W, Jacqz-Aigrain E, Burger D, Danhof M,
Della Pasqua O. Paediatric drug development: are
population models predictive of pharmacokinetics across
paediatric populations? Br J Clin Pharmacol 2011; 72:
454–64.
4 European Medicines Agency. ICH Topic E11: clinical
investigation of medicinal products in the paediatric
population. 2001. Available at http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/
2009/09/WC500002926.pdf (last accessed 3 June 2014).
5 Tsutkawa RK. Selection of dose levels for estimating a
percentage point of a logistic quantal response curve. Appl
Stat 1980; 29: 25–33.
6 Whitehead J, Yinghui Z, Hampson LV, Ledent E, Pereira A. A
Bayesian approach for dose-escalation in a Phase I clinical
trial based on a pharmacodynamic endpoint. J Biopharm
Stat 2007; 17: 1117–29.
7 Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart
GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao
LP. Extrapolation of adult data and other data in pediatric
drug-development programs. Pediatrics 2011; 128: e1242–9.
L. V. Hampson et al.
906 / 78:4 / Br J Clin Pharmacol
8 Nedelman JR, Rubin DB, Sheiner LB. Diagnostics for
confounding in PK/PD models for oxcarbazepine. Stat Med
2007; 26: 290–308.
9 Manolis E, Pons G. Proposals for model-based paediatric
medicinal development within the current European Union
regulatory framework. Br J Clin Pharmacol 2009; 68:
493–501.
10 Jadhav PR, Kern SE. The need for modeling and simulation
to design clinical investigations in children. J Clin Pharmacol
2010; 50: 121S–9S.
11 Piana C, Kliphuis E, Della Pasqua O. Lack of compliance of
European Public Assessment Reports to guidelines for
paediatric drug development before the introduction of
paediatric investigation plans. Clin Trials 2013; 10: 269–79.
12 European Medicines Agency. Concept paper on
extrapolation of efficacy and safety in medicine
development. 2012. Available at http://www.ema
.europa.eu/docs/en_GB/document_library/Scientific
_guideline/2012/06/WC500129285.pdf (last accessed 3 June
2014).
13 R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R Foundation for Statistical
Computing, 2012.
14 European Medicines Agency. Procedure for orphan
medicinal product designation: guidance for sponsors.
2012. Available at http://www.ema.europa.eu/ema/
index.jsp?curl=pages/regulation/document_listing/
document_listing_000268.jsp&mid=WC0b01ac058061f01c
#section1 (last accessed 3 June 2014).
15 European Medicines Agency. Rare disease (orphan)
designations. Available at http://www.ema.europa
.eu/ema/index.jsp?curl=pages/medicines/landing/orphan
_search.jsp&mid=WC0b01ac058001d12b (last accessed 27
February 2013).
16 Patterson S, Jones B. Bioequivalence and Statistics in Clinical
Pharmacology. Boca Raton, USA: Chapman & Hall/CRC, 2006.
17 European Medicines Agency. Guideline on clinical trials in
small populations. 2006. Available at http://www.emea
.europa.eu/docs/en_GB/document_library/Scientific
_guideline/2009/09/WC500003615.pdf (last accessed 3 June
2014).
18 Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in
Phase I cancer clinical trials. J Natl Cancer Inst 2009; 101:
708–20.
19 Carter SK. Study design principles in the clinical evaluation
of new drugs as developed by the chemotherapy
programme of the National Cancer Institute. In: The Design
of Clinical Trials in Cancer Therapy, ed. Staquet MJ. Brussels,
Belgium: Editions Scientific Europe, 1973; 242–89.
20 Lin Y, Shih WJ. Statistical properties of the traditional
algorithm-based designs for phase I cancer clinical trials.
Biostat 2001; 2: 203–15.
21 Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on
precision criteria to derive sample size when designing
pediatric pharmacokinetic studies. J Clin Pharmacol 2012;
52: 1601–6.
22 Speigelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches
to Clinical Trials and Health-Care Evaluation. Chichester, UK:
John Wiley and Sons, 2004.
23 Goodman SN, Sladky JT. A Bayesian approach to
randomized controlled trials in children utilitizing
information from adults: the case of Guillain-Barre. Clin Trials
2005; 2: 305–10.
24 Schoenfeld DA, Zheng H, Finkelstein DM. Bayesian design
using adult data to augment pediatric trials. Clin Trials 2009;
6: 297–304.
25 Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare
diseases: a way out of a conundrum. BMJ 1995; 311: 1621–5.
26 Tan S-B, Dear KBG, Bruzzi P, Machin D. Strategy for
randomised clinical trials in rare cancers. BMJ 2003; 327:
47–9.
27 Billingham L, Malottki K, Steven N. Small sample sizes in
clinical trials: a statistician’s perspective. Clin Invest 2012; 2:
655–7.
28 National Institute for Health Research. Systematic reviews.
2014. Available at http://www.nets.nihr.ac.uk/resources/
systematic-reviews (last accessed 3 June 2014).
Supporting Information
Additional Supporting Information may be found in the









Dose investigations in paediatric drug development
Br J Clin Pharmacol / 78:4 / 907
